To assess the impact of single-nucleotide polymorphisms (SNPs) on predefined severe adverse events in breast cancer (BC) patients receiving (neo-)adjuvant 5-fluorouracil (FU), epirubicin and cyclophosphamide (FEC) chemotherapy.
The clinically most important and most frequently observed adverse event of FEC is bone marrow suppression, which can be life threatening when complicated by an opportunistic infection or bleeding. There is a wide inter-patient variability in developing these adverse events. Despite evidence suggesting a strong correlation between toxicity and the pharmacokinetic (PK) and/or pharmacodynamic (PD) parameters of these agents, they are often dosed based on the body surface area (BSA) [4] [5] [6] [7] . In addition, although obesity has not directly been linked to toxicity associated with anthracyclinecontaining chemotherapy [8] , many centres use(d) capping of the dose when the BSA exceeds 2 m 2 [9] . Although 'limited sampling strategies' can predict PK parameters of cytotoxic anticancer drugs based on a minimal number of blood samples, these methods are technically challenging and not routinely available for clinic use [10] [11] [12] . Some other clinical factors have been proposed as predictors of hematological toxicity, including age, poor performance status, poor nutritional status, female gender, hemoglobin <12 g/dl, liver and renal or cardiovascular disease, but reported effects have generally been too modest to have clinical implications [13] . Therefore, novel clinical predictors of chemotherapy toxicity are urgently needed, allowing introduction of prophylactic measures such as growth factor support, dose modification or alternative chemotherapy regimens.
Genetic variability in enzymes responsible for the metabolism of 5-FU, epirubicin and cyclophosphamide may determine the efficacy and toxicity of FEC treatment. Several studies already assessed the influence of single-nucleotide polymorphisms (SNPs) on toxicity and/or outcome, but most studies have been small in size or were limited to testing only a single or a few SNPs at most, thereby limiting the validity and applicability of the obtained results. The aim of our study was to assess a comprehensive and large set of relevant SNPs in key metabolic genes in a large study cohort receiving the same chemotherapy (FEC) for early BC, and study its correlation with development of short-term severe toxicity.
patients and methods

study population
Since 2000, BC patients visiting the Leuven Multidisciplinary Breast Cancer Center (University Hospitals Leuven, Belgium) have systematically been recruited into a clinical database, containing extensive patient-and tumorrelated information, as well as clinical follow-up such as treatment, relapse and cause of death. A systematic collection of germline DNA was initiated in 2007 for all newly diagnosed BC patients as well as for patients in follow-up. For the present study, we retrieved 1012 BC patients with germline DNA available and treated between 2000-2010 with 3-6 cycles of (neo-)adjuvant FEC. Side-effects were systematically and routinely scored in the medical electronic file at each cycle. Through an electronic chart review, we re-evaluated toxic effects of each patient and also assessed electronic medical notes, hospitalization data and laboratory results. We collected severe toxicities (grade 3-4) using the CTC 3.0 scoring system. Further details are presented in Supplementary Appendix S1, available at Annals of Oncology online.
Blood sampling, collection of patient data and genetic analysis were approved by the local ethics committee (University Hospitals Leuven). All patients included in the study gave written informed consent.
end points
The primary end point was the association between selected SNPs and febrile neutropenia (FN). We focused on FN at any cycle, since the physical and psychological impact of FN, as well as the mechanisms underlying FN, are the same in the first cycle as in any other cycle. Secondary end points were the association between selected SNPs and FN in the first cycle, prolonged grade 4 or deep (<100/µl) neutropenia, anemia grade 3-4, thrombocytopenia grade 3-4 and non-hematological grade 3-4 events.
SNP selection and genotyping
To select relevant SNPs, we first conducted a PubMed search to identify published associations between SNPs and toxicity or clinical outcome of patients treated with 5-FU, anthracyclines and/or cyclophosphamide. We identified 26 SNPs in 16 genes that have previously been linked to efficacy and/or toxicity of one or more of the three drugs (Table 1) . Second, we selected additional SNPs in these genes, as well as in 12 other genes that have functionally been demonstrated to be key modulators of the metabolism of either 5-FU, epirubicin or cyclophosphamide (Table 2) . A comprehensive overview of the key genes critically implicated in the metabolic pathways for each of the three drugs is provided in Supplementary Appendix S2, available at Annals of Oncology online. A total of 33 additional SNPs were selected (of which 13 SNPs were located in the genes from Table 1 and 20 SNPs in 12 novel genes known to be involved in the metabolism of one of the FEC compounds). All selected SNPs represented either common (frequency >5% according to the 1000 Genomes Project [41] ) non-synonymous variants, which are most likely to functionally affect these genes and therefore influence metabolism of the corresponding chemotherapy, or have been reported in the PubMed literature to functionally affect these genes based on previous pharmacogenetic studies with other compounds. Overall, this approach should yield a most comprehensive collection of SNPs affecting the metabolism of FEC chemotherapy. Genotyping of the resulting 59 selected SNPs was carried out using Sequenom MassARRAY (Sequenom Inc., CA) [42] , as described previously. Of these, 50 SNPs were successfully genotyped with an individual call rate of >95%. The overall genotyping call rate of these SNPs was 98.9%. The nine SNPs failed due to technical limitations (e.g. most SNPs were variable tandem repeats, which cannot always be genotyped using Sequenom MassARRAY).
statistical analysis
All continuous data were summarized using means and standard deviations, or medians and interquartile ranges in case data deviated significantly from a normal distribution. Categorical data were summarized using observed frequencies and percentages. The association between SNPs and toxicity during chemotherapy was assessed using Fisher's exact test. Additionally, logistic regression was used to adjust for known predictors of toxicity. For hematological toxicity, logistic regression analyses were adjusted for primary growth factor use (known to have major impact on FN risk), age (generally accepted risk factor for FN), body mass index (BMI) (since the dose for all obese patients was capped using 2 m 2 BSA as the highest BSA, we expected that the BMI could have impact on toxicity) and number of planned cycles. For non-hematological toxicity, logistic regression analyses were adjusted for age, BMI and number of planned cycles. In case homozygous mutant genotypes were rare (<3 out of 1012 patients genotyped), they were grouped with the heterozygous genotype. All tests were two-sided and the statistical significance was set at 5%. Due to the high number of SNPs assessed, corrections for multiple testing were made to preserve the overall Type I error rate by calculating the false discovery rate (FDR) for each of the 50 SNPs assessed [43] . All statistical analyses were carried out using the SAS 9. The variant T-allele increased chemosensitivity of colon and breast cancers (BCs) to 5-FU, but decreased chemosensitivity of BC cells to methotrexate (Sohn et al. [24] ). rs1801131 c.1298A>C Glu429Ala
The rs1801133 T-and rs1801131 C-alleles are linked to clinical response after 5-FU (Etienne-Grimaldi et al. [25] Carriers of the T-allele of rs8192709 were associated with a higher rate of hemorrhagic cystitis and oral mucositis in leukemia patients receiving cyclophosphamide, methotrexate and busulfan (Rocha et al. [27] ).
rs3211371 c.1459C>T Arg487Cys (CYP2B6*5)
More dose delays due to toxicity in CYP2B6*2 and CYP2B6*5 BC patients receiving doxorubicine and cyclophosphamide (Bray et al. [28] ). Women with at least one CYP3A4*1B variant allele had significantly worse DFS after adjuvant cyclophosphamidecontaining chemotherapy (Gor et al. [29] ). GPX4
Glutathione Peroxidase 4 Enzyme involved in the anti-oxidant defense rs713041 c.767T>C Leu220Leu and rs757229 g.1042114G>C N/A Variant alleles of rs713041 and rs757229 were associated with all-cause mortality. Both SNPs were correlated (Udler et al. [30] ).
GSTA1
Glutathione S-transferase alpha 1
Enzyme involved in the detoxification of cyclophosphamide by conjugation of CP metabolites GSTA1*B Study in BC patients treated with cyclophosphamidecontaining regimen. Patients with GSTA1*B/*B genotypes had a longer 5 years survival and a reduced hazard of death (Sweeney et al. [31] ).
GSTP1
Gluthathione S-transferase pi 1
Enzyme involved in the detoxification of cyclophosphamide by conjugation of CP metabolites rs1695 c.313A>G Ile105Val
Systemic Lupus Erythematosus patients carrying one or two Galleles had an increased risk of myelotoxicity and gastrointestinal toxicity when treated with pulsed high-dose cyclophosphamide therapy (Zhong et al. [32] ).
FGFR4
Fibroblast growth factor receptor-4
Tyrosine-kinase receptor involved in a number of cellular processes such as cell growth, differentiation, migration and angiogenesis rs351855 c.1162C>T Gly388Arg
In node-positive patients, receiving CMF adjuvant chemotherapy, the rs351855 T-allele was associated with poor DFS and OS. This association was attributable to poor therapy response in the rs351855 T-allele carriers (Thussbas et al. [33] ). NQO1 NAD(P)H: quinone oxidoreductase 1
The NQO1 enzyme is implicated in protection against oxidative stress and carcinogenesis, including stabilization of the p53 tumor suppressor rs1800566 c.559C>T Pro187Ser
Poor survival rate in epirubicin-treated BC patients due to an impaired response to epirubicin in carriers of the variant Tallele (Fagerholm et al. [34] ).
SOD2 Manganese superoxide dismutase-2
A mitochondrial enzyme that catalyzes the formation of H 2 O 2 from superoxide radicals generated by chemotherapy rs4880 c.47T>C Val16Ala Risks of disease progression and death in metastatic BC patients, receiving high dose cyclophosphamide based regimens followed by autologous stem cell transplantation, were increased in rs4880 TT-genotype carriers (Bewick et al. [35] Carriers of the rs25487 AA-genotype exhibited reduced the risk of recurrence/death (Sun et al. [37] , Jaremko et al. [38] ).
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febrile neutropenia primary end point analyses
We correlated each of the 50 SNPs with the presence or absence of FN using Fischer's exact tests. Carriers homozygous or heterozygous for the variant T-, T-or C-alleles of rs4148350, rs45511401 and rs246221, respectively, in ABCC/ MRP1 were each associated with FN (P = 0.0006, P = 0.007 and P = 0.01, respectively). Adjustment for primary growth factor use, age, BMI and number of planned cycles using logistic regression remained significant for all three SNPs and revealed substantial odds ratios for homozygous carriers of variant T-alleles of rs4148350 (OR = 1.80; 95% CI = 1.11-2.86 and OR = 21.14; 95% CI = 3.07-416.57) for heterozygous or homozygous carriers of the rs4148350 variant (Table 4) . After correction for multiple testing, the association of rs4148350, but not rs45511401 and rs246221 remained significant (FDR = 0.026, 0.16 and 0.19, respectively). Intriguingly, 80% and 25% of homozygous and heterozygous carriers of the mutant rs4148350 T-allele developed FN compared with only 15.7% of wild-type carriers, suggesting that at least homozygous carriers of the rs4148350 T-allele should be recommended for prophylactic measures upon FEC.
Additionally, mutant C-allele carriers of the rs7668282 variant in UGT2B7 were associated with FN (0.6% of FN patients carried a C-allele versus 1.7% of patients without FN; P = 0.02; FDR = 0.28). Likewise, homozygous carriers of a mutant rs351855 T-allele in FGFR4 were less common in patients with FN (5.8% versus 10.1%; P = 0.04; FDR = 0.38). We did not observe any significant association for the other SNPs.
secondary hematological and non-hematological end point analyses
We assessed the association between individual SNPs and secondary end points (Table 5) . Carriers homozygous or heterozygous for the mutant rs4148350 T-allele of ABCC/ MRP1 were associated (i) with FN in the first cycle, (ii) prolonged grade 4 or deep (<100/µl) neutropenia and (iii) thrombocytopenia (P = 0.01, 0.002 and 0.007, respectively). After correction for multiple testing, only the correlation with prolonged grade 4 or deep neutropenia remained significant (FDR = 0.04). All other SNPs that correlated with FN in the primary end point analysis were associated with at least one of the secondary end points ( Table 5 ). The association with prolonged grade 4 or deep neutropenia of mutant rs7668282 C-allele carriers in UGT2B7 also remained significant after correction for multiple testing (FDR = 0.045). Some additional SNPs correlated with secondary hematological end points, but not with the primary end point. None of these SNPs, however, passed the threshold for multiple testing for any of the secondary end points. [39]). rs1799793 c.934G>A Asp312Asn Severe neutropenia was associated with XPD 312 Asp/Asn in ovarian cancer patients receiving the cisplatincyclophosphamide regimen (Khrunin et al. [40] ).
Since rs25487 in XRCC1 could not be genotyped, we selected the rs25486 variant, which is in full linkage disequilibrium with rs25487, for genotyping. Since rs713041 and rs757229 in GPX4 were highly linked, we only selected rs757229 for genotyping. Likewise, since CYP2B6*1B, CYP2B6*1G, CYP2B6*13B were highly linked, we only selected CYP2B6*1B for genotyping. Of all 26 selected SNPs we attempted to genotype, the following five SNPs failed genotyping: rs3211371, rs4880, GSTA1*B, CYP2B6*1B and TSER. DFS, disease-free survival; CMF, cyclophosphamide-methotrexate-fluorouracil; OS, overall survival; PFS, progression-free survival; G, guanine; C, cytosine; T, thymine; A, adenine. The rs1138272 was predictive in the adjuvant and metastatic setting of colorectal cancer patients treated with the 5-FU/leucovorin/ oxaliplatin (FOLFOX4) regimen (Cecchin et al. [54] ). Selected because missense mutations are likely to affect gene function.
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the mutant rs351855 T-allele in FGFR4 were associated with non-hematological grade 3-4 events (P = 0.03 and 0.03, respectively), but FDR values were high (0.58 and 0.58, respectively; Table 5 ). We did not find an association for any of the other SNPs.
discussion
In the present study, we identified three common SNPs in ABCC1/MRP1, i.e. rs246221, rs4148350 and rs45511201, each significantly associated with an increased risk of hematological toxicity during FEC chemotherapy. The ABCC subfamily contains 12 transporters with a diverse functional spectrum that includes ion transport, cell surface receptor and toxin secretion activities. The human ABCC1/MRP1 gene is mainly involved in energy-dependent transport of cytotoxic agents out of the cell [44] , it is a membrane-bound glycoprotein that is almost ubiquitously expressed in different cell types, including anthracycline-resistant tumor cells [45, 46] . The cells overexpressing MRP1 are resistant to a wide variety of anticancer drugs, such as doxorubicin (Adriamycin, Pfizer, Teva, ScheringPlough) and epirubicin [47] . Furthermore, the antitumor effect of epirubicin on tumor cells dramatically improves both in vivo and in vitro by inhibiting ABCC1/MRP1 [48] . At the genetic level, several variants in ABCC1/MRP1 have previously been correlated with anthracycline-induced cardiotoxicity (ACT). One study investigated nine ABCC/ MRP1 SNPs and observed that common rs3743527 TT-and rs246221 TC/TT-genotype combinations were associated with ACT [15] . Likewise, two other studies reported a similarly increased risk of ACT with the variant rs4148350 and rs45511401 T-alleles [16, 17] . Although we did not assess cardiotoxicity in our study, we observed that variant rs246221 and rs4148350 alleles were associated with other FEC-induced toxic effects. In particular, we observed that both variants in ABCC1/MRP1 were associated with FN and prolonged grade 4 neutropenia even after correction for multiple testing. The fact that variant alleles of both SNPs were consistently associated with ACT in previous studies [15] [16] [17] and FEC-induced hematological toxicity in the current study suggests that the observed association does not represent a spurious association. The three SNPs in ABCC1/MRP1 did not occur independently from each other. In particular, rs4148350 and rs45511401 were in strong linkage disequilibrium (r 2 = 0.92), whereas rs246221 was in moderate linkage with the other two SNPs (r 2 = 0.31 and r 2 = 0.20 relative to rs45511401 and rs4148350, respectively). Since rs45511401 encodes a Gly671Val nonsynonymous mutation, whereas rs4148350 represents an intronic ABCC1/MRP1, rs45511401 most likely represents the causal variant underlying the association with toxicity. Functional studies have shown that cells carrying variant rs4511401 genotypes have impaired MRP1 efflux capacity of 4-hydroxy-2-trans-nonenal, which is a highly reactive and toxic lipid aldehyde that is formed in cells exposed to doxorubicin [49] . Overall, this suggests that decreased efflux of FEC chemotherapy or any of the toxic metabolites arising due to FEC chemotherapy will increase toxicity in carriers of the variant rs4511401 allele.
An important observation is that 80% and 25% of homozygous and heterozygous carriers of the variant rs4148350 or rs45511401 alleles in ABCC1/MRP1 developed FN compared with only 15.7% of wild-type GG-carriers. The guidelines from the European Organization for Research and The rs861534 SNP was associated with longer OS in early BC patients receiving adjuvant chemotherapy. In the patient's subgroup receiving anthracyclines XRCC3 rs861534 was associated with improved OS (Marcos et al. [63] ).
The rs2273697, rs11572080, rs56489507 and rs3957356 SNPs failed genotyping on Sequenom MassARRAY. The rs861534 variant also failed, but was captured by genotyping the synonymous SNP rs861539.
a Selection of extra genes based on current knowledge of genes involved in the metabolism of 5-FU, epirubicin and cyclophosphamide (see also Supplementary Appendix S2, available at Annals of Oncology online). SNP in DNA repair pathways, which are activated after DNA damage by chemotherapy, can potentially influence metabolism and toxicity but also efficacy of the chemotherapy.
original articles Annals of Oncology Treatment of Cancer (EORTC) recommend primary prophylaxis with colony stimulating factors if the incidence of FN is expected to be more than 20% following chemotherapy [50] . If our data are confirmed, genetic testing for rs4148350 or rs45511401 could be offered to assess the risk of FN, and to direct the use of growth factors or alternative chemotherapy regimens. The socioeconomic burden of genotyping patients and preventing toxic complications associated with FEC in high-risk patients is expected to be lower than treating the sometimes life-threatening side-effects of FEC therapy, with subsequent dose reductions, delays or interruptions that can also increase the risk of relapse [51] . The predictive capacity of the examined SNPs for thrombocytopenia and anemia was less obvious, but this is a more infrequent problem with FEC chemotherapy compared with neutropenia-related events. Analysis of the DPD gene in 14 patients who developed severe 5-FU toxicity and were characterized by reduced DPD activity revealed the presence of mutations in 11 of 14 patients. The most commonly observed mutation was the splice site mutation IVS14+1G>A (rs3918290) [18] . The rs1801133 variant in MTHFR was correlated with increased chemotherapy sensitivity to 5-FU in colon and BC cells [24] , whereas in another study rs1801133 and rs1801131 in MTHFR were both correlated to the response rate in patients receiving FOLFOX, which is a 5-FU-containing regimen [25] . In our study, we did not observe any association with The number of missing data was as follows: tumor grade (n = 20), ER status (n = 1), HER2 status (n = 4), pT (n = 2), pN (n = 1), cT (n = 17) and cN (n = 13). For all other variables, there were no missing data. Is, in situ; TC, docetaxel-cyclophosphamide; FEC, 5-fluorouracil (5-FU), epirubicin, cyclophosphamide. *Uncorrected P values were calculated using Fisher's exact tests. **Corrected P values were obtained using a logistic regression for presence or absence of FN while including the following covariates: SNP, primary growth factor use, age, body mass index (BMI) and number of planned cycles. OR, odds ratio using wild type as reference category; FDR, false discovery rate. In case homozygous mutant genotypes were rare (less than 3 out of 1012 patients genotyped), they were grouped with the heterozygous allele. There were missing genotypes for the rs45511401 (n = 2), rs4148350 (n = 5), rs246221 (n = 7), rs76688282 (n = 8) and rs351855 (n = 8) variants.
original articles Annals of Oncology toxicity and rs3918290 and only found a moderate correlation between rs1801131 and non-hematological toxicity. The absence of a significant association with variants in both the genes probably relates to the fact that 5-FU toxicity is not frequent in BC patients treated with FEC due to a much lower 5-FU dose in breast compared with colorectal cancer patients. Leukocytopenia was significantly related to the rs7254579, rs4802101 and rs2279345 variants in CYP2B6 in lymphoma or BC treated with cyclophosphamide (500-750 mg/m 2 ) [26] . Furthermore, rs8192709 and rs2279343 in CYP2B6 were associated with oral mucositis and hemorrhagic cystitis in leukemia patients receiving chemotherapy in the context of stem cell transplantation [27] , and with dose delays due to toxicity in BC patients [28] . In our study, we could not find any association with toxicity for any of the CYP2B6 SNPs tested; this might also be related to the fact that the dose of cyclophosphamide in the FEC regimen is much lower than in other studied regimens (certainly older schedules where highdose cyclophosphamide was used). The fact that we mainly find an association between an SNP in an epirubicin-related gene (ABCC1) and toxicity is consistent with the fact that epirubicin is the most toxic of the three compounds at the doses used in the FEC regimen. 5-Fluorouracil and cyclophosphamide are given at doses much below the maximum-tolerated dose. It is, therefore, not unexpected that genetic variations in genes metabolizing these compounds are not strong predictors of severe toxicity. Corrected P values are generated using logistic regression for presence or absence of secondary end points, while correcting for the following covariates: SNP, primary growth factor use (FN, first cycle only), age, body mass index (BMI) and number of planned cycles. FDR: false discovery rate. In case homozygous mutant genotypes were rare (<3 out of 1012 patients), they were combined with the heterozygous genotype. There were missing genotypes for rs45511401 (n = 2), rs4148350 (n = 5), rs246221 (n = 7), rs2231137 (n = 7), rs76688282 (n = 8), rs351855 (n = 8), rs1801131 (n = 11) and rs13181 (n = 13).
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In a more exploratory analysis, we also investigated SNPs that previously had not been correlated with FEC-induced toxicity, but that were non-synonymous variants located in genes well known to metabolize either 5-FU, epirubicin or cyclophosphamide. We only found a moderate correlation between hematological toxicity and rs7668282 in UGT2B7, a gene that is important for the inactivation of epirubicin. The rs7668282 variant is located at position-79 in the UGT2B7 promoter. Previous studies have indicated that variant alleles lower transcriptional activity of the UGT2B7 promoter by 2.5-to 7-fold, resulting in much lower serum morphine glucuronide concentrations in patients with cancer who received long-term oral morphine therapy [52] .
A weakness of this study is its retrospective design and that we have only focused on severe acute toxicity, without collecting information on moderate or long-term hematological and non-hematological adverse events. However, an advantage of focusing on severe acute toxic effects is that it is unlikely that we missed any relevant events (even if retrospectively assessed). A more refined prospective study that focuses on the severity of each toxicity, including moderate toxic effects such as sub-clinical cardiac events, would be very interesting in the future. We also did not have sufficient followup data to carry out a statistically relevant analysis for longterm side-effects, such as cardiac toxicity, neither could we assess the effect on BC relapse and survival. In particular, the current median follow-up was relatively short (3.8 years) and the number of events was low (currently 52 deaths of which 47 were BC-related, 45 loco-regional and 102 distant relapses). We intend to carry out a survival analysis of the current dataset after 8 years of follow-up, and will also assess late-onset cardiotoxicity. Importantly, our study also has a number of strengths. To the best of our knowledge, it is based on the largest BC cohort that ever has been studied in relation to genetic risk factors predictive of FEC-induced toxicity. Despite the size of this cohort, all patients were homogeneously treated with the same FEC regimen. Furthermore, thanks to the sample size of this study, we were able to genotype a large and systematic set of SNPs and detect clinically relevant associations, while correcting for multiple testing.
In conclusion, our extensive analysis of 50 genetic variants identified three SNPs in ABCC1/MRP1 predictive of severe adverse hematological events associated with FEC chemotherapy. Our results confirm the importance of the patient's genetic profile in predicting toxicity allowing preventive measures. Many of the other SNPs that have previously been shown to correlate with toxicity and/or clinical outcome in small patient groups could not be validated.
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